Marvell Technology (NasdaqGS:MRVL) has completed its acquisitions of Celestial AI and XConn Technologies. The deals expand Marvell's AI hardware and data center networking capabilities and deepen ties with major cloud providers, including Amazon. These transactions mark a shift toward custom silicon for AI workloads and away from lower margin business lines. Marvell is a key supplier of semiconduc...
Marvell Technology (NasdaqGS:MRVL) has completed its acquisitions of Celestial AI and XConn Technologies. The deals expand Marvell's AI hardware and data center networking capabilities and deepen ties with major cloud providers, including Amazon. These transactions mark a shift toward custom silicon for AI workloads and away from lower margin business lines. Marvell is a key supplier of semiconductor solutions for data centers, cloud providers and networking customers, and AI has become a...
The Unsettling Truths The Epstein Files Reveal About Power And Privilege Authored by Patrick Keeney via The Epoch Times (emphasis ours), The public fixation on the Epstein files has settled, predictably, on the most lurid elements of the story. This is understandable. Sexual exploitation, particularly of the young, is among the most corrosive of crimes, and the scale of Epstein’s abuse, as well as...
The Unsettling Truths The Epstein Files Reveal About Power And Privilege Authored by Patrick Keeney via The Epoch Times (emphasis ours), The public fixation on the Epstein files has settled, predictably, on the most lurid elements of the story. This is understandable. Sexual exploitation, particularly of the young, is among the most corrosive of crimes, and the scale of Epstein’s abuse, as well as the apparent indifference of powerful institutions to it, demands moral outrage. But to focus exclusively on the sexual scandal is to miss the deeper and more unsettling lesson the affair reveals. Documents that were included in the U.S. Department of Justice release of the Jeffrey Epstein files are photographed on Jan. 2, 2026. Jon Elswick/AP Photo What the Epstein files expose, above all, is the social and moral estrangement of American elites from the people they claim to govern. Epstein was not merely a predator who gained access to power. He was a node within a closed world of wealth, influence, and immunity. The scandal is not that powerful people behaved badly in private—history shows many such examples—but that they did so with a confidence rooted in the belief they were insulated from the consequences of their behavior. They moved through a transnational elite culture that had largely severed itself from ordinary moral constraints, legal accountability, and civic obligation. That culture did not merely tolerate Epstein but normalized him. This echoes the point Christopher Lasch made decades ago, long before private islands and hedge-fund philanthropy became familiar symbols of elite excess. In his 1994 book “The Revolt of the Elites,” Lasch argued that the modern American ruling classes had stopped seeing themselves as stewards of a shared national project. Instead, they increasingly saw themselves as a mobile, globalized caste, educated in the same institutions, moving through the same cities, governed by the same tastes, and primarily accountable only to each ot...
dragana991/iStock via Getty Images ARS Pharmaceuticals, Inc. ( SPRY ) is a commercial-stage biopharmaceutical company that produces Neffy for type I allergic reactions, including anaphylaxis. This asset is a needle-free intranasal epinephrine dose, which offers a more convenient route of administration than the traditional injectable epinephrine. Neffy has been experiencing an increasing growth in...
dragana991/iStock via Getty Images ARS Pharmaceuticals, Inc. ( SPRY ) is a commercial-stage biopharmaceutical company that produces Neffy for type I allergic reactions, including anaphylaxis. This asset is a needle-free intranasal epinephrine dose, which offers a more convenient route of administration than the traditional injectable epinephrine. Neffy has been experiencing an increasing growth in sales since its launch last year due to its comparable efficiency to auto-injectors, with a simpler administration and reduced potential for user error. SPRY’s pipeline also includes ARS-2, which is an intranasal epinephrine program for chronic spontaneous urticaria acute flares. This candidate is now in Phase 2b, and SPRY plans to release its data readout by 1H2026. Neffy And Epinephrine ARS Pharmaceuticals, Inc. is a biopharmaceutical company that develops needle-free products to treat severe allergic reactions. This means that one of its key addressable markets is in treating anaphylaxis. SPRY was founded back in 2015 and is currently headquartered in San Diego, California. I previously covered SPRY in February last year, and since then, the stock has seen considerable price swings. Yet, as of the time of this writing, SPRY is down about 30.9%, so I thought it was worthwhile updating my analysis on this name. Source: Corporate Presentation. November 2025. As a quick recap, SPRY’s portfolio contains an epinephrine spray called Neffy. This is SPRY’s FDA-approved intranasal medication indicated for type I allergic reactions that are fast and can escalate to life-threatening emergencies. Fortunately, SPRY has positioned its nasal spray as a convenient solution, especially compared to other traditional epinephrine auto-injectors that can be much more cumbersome during emergencies. It’s also worth highlighting that this product was launched in May 2025. As of Q3 2025, Neffy’s quarterly sales reached $31.3 million, which is impressive given that it only did $7.8 million in rev...
Dragon Claws/iStock via Getty Images By Bryan Cutsinger Shelter and energy costs led the deceleration. While inflation remains above the Fed’s target, the monthly price growth neared a multi-year low. Inflation cooled more than expected in January, the Bureau of Labor Statistics (BLS) reported on Friday. The Consumer Price Index (CPI) rose 0.2 percent last month, down from 0.3 percent in December....
Dragon Claws/iStock via Getty Images By Bryan Cutsinger Shelter and energy costs led the deceleration. While inflation remains above the Fed’s target, the monthly price growth neared a multi-year low. Inflation cooled more than expected in January, the Bureau of Labor Statistics (BLS) reported on Friday. The Consumer Price Index (CPI) rose 0.2 percent last month, down from 0.3 percent in December. On a year-over-year basis, headline inflation fell from 2.7 percent in December 2025 to 2.4 percent in January 2026 — the lowest reading since May 2025. Core inflation, which excludes volatile food and energy prices, rose 0.3 percent in January, up from 0.2 percent in December. It eased to 2.5 percent on a year-over-year basis, down from 2.6 percent in the prior month. The January reading marks the slowest annual pace for core CPI since March 2021. The latest inflation data are especially encouraging when viewed against historical patterns. Research from the Federal Reserve Bank of Boston shows that January inflation has consistently run higher than other months over the past quarter-century, owing to residual seasonality, the tendency for firms to change prices at the start of the year, and compositional effects in sectors that typically adjust prices in January. That January 2026 came in at just 0.2 percent (below the historical January average), suggesting that underlying inflation pressures are genuinely moderating. The moderation in headline inflation was driven primarily by energy prices, which fell 1.5 percent in January. Gasoline prices declined, and utility costs moderated. Food prices rose a modest 0.2 percent, with food at home and food away from home both posting smaller increases than in recent months. Shelter costs, which account for roughly one-third of the index, rose 0.2 percent - a notable deceleration from the 0.4 percent increase in December. The slower pace of shelter inflation is welcome news, as this category has been one of the most persistent sourc...
Casey Wasserman said he is putting his talent and marketing agency up for sale, citing past personal mistakes that have had an effect on the company. The sports and entertainment talent agent said in a memo to staff on Friday night that he had “become a distraction” to the company’s work and had started the process to sell the firm. Mike Watts, a longtime executive, would take on day-to-day contro...
Casey Wasserman said he is putting his talent and marketing agency up for sale, citing past personal mistakes that have had an effect on the company. The sports and entertainment talent agent said in a memo to staff on Friday night that he had “become a distraction” to the company’s work and had started the process to sell the firm. Mike Watts, a longtime executive, would take on day-to-day control of the business, he said. Wasserman’s name came up in the trove of Jeffrey Epstein-related documents and emails released last month by the US Justice Department. The files contained flirtatious 2003 email exchanges between Wasserman and Ghislaine Maxwell , an Epstein confidante who is serving a 20-year prison sentence for recruiting girls for sexual abuse by Epstein and for participating in some of the assaults. Wasserman has said he went on a 2002 humanitarian trip as part of a delegation with the Clinton Foundation and traveled on Epstein’s plane. He said he never had a personal or business relationship with Epstein and apologized for having any association with either Maxwell or Epstein. “I’m deeply sorry that my past personal mistakes have caused you so much discomfort,” he wrote. “It’s not fair to you, and it’s not fair to the clients and partners we represent so vigorously and care so deeply about.” The Wall Street Journal earlier reported on Wasserman’s memo to employees.
Klaus Vedfelt/DigitalVision via Getty Images Introduction It’s been a while since my last piece on ATS Corporation ( ATS:CA )( ATS ) back in August 2024. Since then, the company has shown impressive organic growth despite a softer macro environment. While shares have lagged the S&P 500’s return of 26% with a return of 16% since my last update, I think shares are still worthy of a ‘buy’ given the r...
Klaus Vedfelt/DigitalVision via Getty Images Introduction It’s been a while since my last piece on ATS Corporation ( ATS:CA )( ATS ) back in August 2024. Since then, the company has shown impressive organic growth despite a softer macro environment. While shares have lagged the S&P 500’s return of 26% with a return of 16% since my last update, I think shares are still worthy of a ‘buy’ given the renewed focus on margin expansion going forward. Recent Results ATS reported strong results for its Q3’26 results with a beat on both the top and bottom line. During the quarter, ATS put up revenues of $761 million, which came in 16.7% higher compared to last year and was $38 million ahead of consensus estimates. Most of this was organic growth (12.6%), with a smaller (4.1%) lift from FX translation. Seeking Alpha When looking at the results by segment, Life Sciences revenues, the company’s largest segment at 51% of total revenues, was up 4% compared to last year, and the company’s backlog is full of radiopharma and GLP-1 auto-injector programs. Total company order bookings reached $821 million, up nearly 12% sequentially despite a 7% year on year decline tied to normalized Transportation activity and lapping prior large enterprise wins. That puts the company’s book-to-bill ratio at 1.06:1 and the backlog at $2.05 billion, roughly unchanged from last year. When looking at the backlog composition below, there’s been a dip in Life Sciences with record numbers in Energy and Consumer Products. Company Filings Company Filings With a new CEO that took the helm in January who has a focus on profitability, I’d expect ATS to continue making more progress on its margins. This quarter, gross margins dipped 111 bps to 29.6%, a move I view as largely attributable to program mix timing rather than any structural issue. The reason for this was there was a lot more lower-margin nuclear refurbishment work ramping up while still contributing positively to the bottom line. To illustrate that, ...
Hong Kong police are investigating the death of an 80-year-old man allegedly knocked down by a taxi driver in a traffic accident in Kwun Tong. The force said on Saturday that the cab driver, a 46-year-old man, was travelling along Kwun Tong Road on Friday night when he was believed to have struck the pedestrian near Ngau Tau Kok Road. The elderly man was reportedly crossing the road at the time. P...
Hong Kong police are investigating the death of an 80-year-old man allegedly knocked down by a taxi driver in a traffic accident in Kwun Tong. The force said on Saturday that the cab driver, a 46-year-old man, was travelling along Kwun Tong Road on Friday night when he was believed to have struck the pedestrian near Ngau Tau Kok Road. The elderly man was reportedly crossing the road at the time. Police said the victim sustained serious injuries to his head and limbs and lost consciousness. He...